Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

An oral alternative to injectable treatment for uncomplicated gonorrhoea could be on the way in the US, as FDA starts review of GSK's gepotidacin.

More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.

Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.

The FDA has launched a programme to make it easier for drug companies to set up manufacturing facilities in the US and reduce the country's reliance on imported medicines. Today, the regulator ...

This Q2 clinical trials round-up highlights key developments from early-phase breakthroughs to pivotal trial readouts, underscoring the sector’s commitment to precision medicine, immunotherapy ...

Adding Nykode Therapeutics' VB10.16 vaccine to treatment with Roche's cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer.